AN NMR-STUDY OF THE COVALENT AND NONCOVALENT INTERACTIONS OF CC-1065 AND DNA

被引:63
|
作者
SCAHILL, TA
JENSEN, RM
SWENSON, DH
HATZENBUHLER, NT
PETZOLD, G
WIERENGA, W
BRAHME, ND
机构
[1] Research Laboratories, Pharmaceutical Research and Development Division, The Upjohn Company, Kalamazoo
[2] Visiting Scientist at the National Center for Tox-icological Research, Jefferson
[3] Bio-Rad Laboratories, Hercules, CA 94547
关键词
D O I
10.1021/bi00463a031
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The binding of the antitumor drug CC-1065 has been studied with nuclear magnetic resonance (NMR) spectroscopy. This study involves two parts, the elucidation of the covalent binding site of the drug to DNA and a detailed investigation of the noncovalent interactions of CC-1065 with a DNA fragment through analysis of 2D NOE (NOESY) experiments. A CC-1065-DNA adduct was prepared, and an adenine adduct was released upon heating. NMR (1H and 13C) analysis of the adduct shows that the drug binds to N3 of adenine by reaction of its cyclopropyl group. The reaction pathway and product formed were determined by analysis of the 13C DEPT spectra. An octamer duplex, d(CGATTAGC-GCTAATCG), was synthesized and used in the interaction study of CC-1065 and the oligomer. The duplex and the drug-octamer complex were both analyzed by 2D spectroscopy (COSY,NOESY). The relative intensity of the NOEs observed between the drug (CC-1065) and the octamer duplex shows conclusively that the drug is located in the minor groove, covalently attached to N3 of adenine 6 and positioned from the 3’→ 5’ end in relation to strand A [d(CGATTA6GC)]. A mechanism for drug binding and stabilization can be inferred from the NOE data and model-building studies. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:2852 / 2860
页数:9
相关论文
共 50 条
  • [1] REVERSIBILITY OF THE COVALENT REACTION OF CC-1065 AND ANALOGS WITH DNA
    WARPEHOSKI, MA
    HARPER, DE
    MITCHELL, MA
    MONROE, TJ
    BIOCHEMISTRY, 1992, 31 (09) : 2502 - 2508
  • [2] THE COVALENT BINDING OF THE ANTI-TUMOR ANTIBIOTIC, CC-1065, TO DNA
    SWENSON, DH
    WOODLEY, BJ
    PETZOLD, GL
    SCAHILL, TA
    KAPLAN, DJ
    HURLEY, LH
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 248 - 248
  • [3] DNA-SEQUENCE RECOGNITION BY THE ANTITUMOR ANTIBIOTIC CC-1065 AND ANALOGS OF CC-1065
    KRUEGER, WC
    HATZENBUHLER, NT
    PRAIRIE, MD
    SHEA, MH
    CHEMICO-BIOLOGICAL INTERACTIONS, 1991, 79 (03) : 265 - 286
  • [4] ON THE MECHANISM OF INTERACTION OF CC-1065 WITH DNA
    SWENSON, DH
    KRUEGER, WC
    PETZOLD, GL
    WALLACE, TL
    LI, LH
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1982, 23 (MAR): : 196 - 196
  • [5] THEORETICAL-STUDY OF THE SEQUENCE SPECIFICITY IN THE COVALENT BINDING OF THE ANTITUMOR DRUG CC-1065 TO DNA
    ZAKRZEWSKA, K
    RANDRIANARIVELO, M
    PULLMAN, B
    NUCLEIC ACIDS RESEARCH, 1987, 15 (14) : 5775 - 5785
  • [6] CC-1065 PARTIAL STRUCTURES - ENHANCEMENT OF NONCOVALENT AFFINITY FOR DNA MINOR GROOVE BINDING THROUGH INTRODUCTION OF STABILIZING ELECTROSTATIC INTERACTIONS
    BOGER, DL
    SAKYA, SM
    JOURNAL OF ORGANIC CHEMISTRY, 1992, 57 (04): : 1277 - 1284
  • [7] (+)-CC-1065 DNA ALKYLATION - KEY STUDIES DEMONSTRATING A NONCOVALENT BINDING SELECTIVITY CONTRIBUTION TO THE ALKYLATION SELECTIVITY
    BOGER, DL
    MUNK, SA
    ZARRINMAYEH, H
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1991, 113 (10) : 3980 - 3983
  • [8] Molecular modeling study of binding between DNA and CC-1065 analogue
    Sun, GY
    Nicklaus, MC
    Simmons, DP
    Lai, LY
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U1342 - U1342
  • [9] REACTION OF CC-1065 AND SELECT SYNTHETIC ANALOGS WITH DNA
    HURLEY, LH
    LEE, CS
    MCGOVREN, JP
    WARPEHOSKI, MA
    MITCHELL, MA
    KELLY, RC
    ARISTOFF, PA
    BIOCHEMICAL PHARMACOLOGY, 1988, 37 (09) : 1795 - 1796
  • [10] INHIBITION OF T4 DNA-LIGASE ACTIVITY (+)-CC-1065 - DEMONSTRATION OF THE IMPORTANCE OF THE STIFFENING AND WINDING EFFECTS OF (+)-CC-1065 ON DNA
    SUN, DK
    HURLEY, LH
    ANTI-CANCER DRUG DESIGN, 1992, 7 (01): : 15 - 36